[ad_1]
Photo by Justin Tallis (AFP / Scanpix)
The American company Novavax reports that tests in the United Kingdom (United Kingdom) and South Africa show that its vaccine against COVID-19 is 89.3% effective.
The company claims that the vaccine is 95.6% effective against the most common coronavirus strain and 85.6% against the new strain found in the UK. However, it is less effective in protecting against the strain found in South Africa (60% effective among people without HIV).
Stan Novas, director of Novavax, says the study results are impressive and “as good as we could have hoped for.” He also states that the effectiveness against the African variety “exceeded expectations”.
Novavax’s Phase III clinical trials in the UK involve more than 15,000 people between the ages of 18 and 84, 27% of whom are over 65 years of age.
British Prime Minister Boris Johnson welcomed the “good news” and said the vaccine will now be evaluated by a UK drug regulator.
The United Kingdom has agreed with Novavax 60 million euros doses of this vaccine that will be produced in a factory in England.
According to the government, these doses are expected to be released for use in the second half of the year if approved by the Medicines and Health Regulatory Agency.
There are currently three vaccines approved and used in the UK: Modernos, BioNTech / Pfizer and AstraZenecos. The Modernos and BioNTech / Pfizer vaccines are currently being vaccinated in the EU, but the European Medicines Agency should consider approval of the AstraZeneca vaccine starting this Friday.
VŽ wrote that Germany had doubts about the efficacy of the AstraZeneca vaccine. The National Immunization Commission has ruled that the company has not provided enough data on whether the vaccine it has developed is really effective in the elderly.
The European Commission has completed exploratory talks with Novavax. Under the planned deal with Novavax, all EU Member States could buy 100 million euros. doses and could acquire up to an additional 100 million. dose.
The EU has recently been embroiled in disputes with vaccine manufacturers who have repeatedly stated that they will not be able to deliver on their previous promises on vaccine volumes and delivery schedules.
Write a comment
[ad_2]
